1997. Axid - Eli Lilly and American Home Products‚ and launched in May 1988. 1993 sales at $271 million. Patent expiry in 2000. Timeline of the case: August 1977 SmithKline launches Tagamet to treat ulcers‚ and later from 1989‚ SmithKline Beecham markets it June 1983 Glaxo introduces Zantac 1985 SmithKline starts discussions with FDA on the OTC launch of Tagamet‚ named Tagamet HB November 1986 Merck introduces Pepcid‚ and later from 1989‚ JJM markets it May 1988 Eli Lilly introduces Axid
Premium
STUDY QUESTIONS Eli‚ Lilly 1998 (A): Strategic Challenges 1. What were the strategic challenges for pharmaceutical companies in the 1990s? 2. How did Lilly respond to these challenges? How does globalization allow Lilly to better cope with them? 3. Suppose that you are a top manager of a Korean pharmaceutical company. How would you formulate your strategy in the face of pharma giants’ (like Lilly) aggressive strategic moves toward globalization? Taiwan Semiconductor Manufacturing
Premium Saudi Arabia Semiconductor Strategic management
driving to office where in an hour he was to meet with the marketing team of Viagra‚ one of Pfizer’s blockbuster drugs. They were to determine the marketing strategy of Viagra in the US‚ given the entry of two key players‚ Bayer/Glaxo SmithKline and Eli Lilly. Both these companies were slated to launch competing products for the treatment of erectile dysfunction (ED) in the US market. When Viagra‚ a non-prescription drug to treat male impotence‚ was launched just five years ago‚ the little blue pill spawned
Premium Erectile dysfunction
significance of these applications to the company is the bandwidth that supports them. Judd’s increased the bandwidth by a magnitude of about 900 percent in the 1990s without cost-benefit analysis. Eli Lilly & Company A very large pharmaceutical company with headquarters in Indianapolis‚ Eli Lilly has a proactive attitude toward new technologies. It began exploring the potential of the Internet in 1993. Managers soon realized that‚ by using intranets‚ they could reduce many of the problems associated
Premium
Presentation on: Pfizer and the Pharmaceutical Industry Fletcher Leung Analyst Investment Analysis Group February 15‚ 2002 Presentation Agenda • Industry Overview: Research Based Pharmaceuticals • Pfizer – Company Specifics – Performance – Growth Drivers • Valuation – Comparables Analysis – DCF • Recommendation February 15‚ 2002 Page 2 Investment Analysis Group 1 Industry Overview Economic •Cost Effective Demographic Sociocultural •Aging Population
Premium
Case-3 1) In your judgment‚ is it wrong‚ from ethical point of view‚ for the auto companies to submit plans for an automobile to China? Explain your answer. In environmental point of view‚ where my ethic point of view strongly relies on‚ on international auto companies to submit plans for an small automobile enough to carry three people‚ rugged enough to commute across poor maintained roads across nation generating a minimum pollution automobile costing less than $5‚000 dollars is not such a
Premium Ethics
Introduction Ranbaxy’s Laboratories Limited’s (Ranbaxy) profile as a pharmaceutical company underwent a sea change during the period 1985-1995. During this period Ranbaxy diversified into different products‚ markets and in general over the ‘value curve’. Its export sales grew from 7.45% of total sales in 1985 to 42.4% of total sales 1995. The growth in the foreign markets was primarily led by bulk drugs and intermediates‚ which constituted 80% of the foreign sales in 1995. Driven by the vision
Free Developed country Developing country Emerging markets
------------------------------------------------- ------------------------------------------------- BRISTOL-MEYERS SQUIBB FINANCIAL ANALYSIS A BRISTOL MEYERS SQUIBB AMYLIN MERGER ANALYSIS: RICHARD LATIMER UMUC FINANCE MAJOR Executive Summary On August 9th Bristol-Meyers Squibb successfully completed the tender offer for all of the outstanding shares of common stock of Amylin Pharmaceuticals Inc (NASDAQ: AMLN) at a purchase price of $31.00 per share. As of the expiration of the
Premium Revenue Financial ratios Income statement
Stating the Canadian perspective of the essential facilities doctrine‚ such doctrine has not been dealt‚ but courts have faced the challenges under the issue of the IPR and have paced it under the IPR‚ the Canadian have an same perspective of harmonizing and balancing the two aspects of laws‚ to which perspective of Canadian becomes an integral part of discussion. Various interesting cases that have been dealt by the Canadian Judiciary and statutes having bearing on IP and competition law will be
Premium Canada Law Canadian Charter of Rights and Freedoms
CSR Content Analysis on Novo Nordisk Novo Nordisk is a global company based in Denmark operates in the pharmaceutical and healthcare industry. In pursuit of corporate sustainability‚ Novo Nordisk operates in accordance with the Triple Bottom Line principle which balances financial‚ social and environmental considerations. In 2013‚ 78.32% of Novo Nordisk’s total revenue was generated from diabetes care products‚ thus sustainability initiatives relevant to this core activity are important to the company
Premium Renewable energy Corporate social responsibility Growth hormone